Unforeseen Setbacks in the Effort to Combat Neglected Tropical Diseases

For the past several years, the global initiative to tackle neglected tropical diseases (NTDs) looked promising. Financial backing from USAID played a pivotal role in this progress, particularly in regions like Mali.

In a small community in Mali, a woman named Diango Tounkara began experiencing night blindness around 2018. Initially unaware of the cause, her condition was eventually diagnosed as trachoma—a preventable disease leading to blindness if untreated.

In 2022, a U.S.-funded program provided Tounkara with necessary medical interventions, such as antibiotics and eyelid surgery, to prevent the disease's progression. This program was part of a comprehensive effort to battle various NTDs, including trachoma.

"Without this timely intervention, blindness would have taken over my life," Tounkara revealed. Her experience was not isolated; she had been combating these diseases at the grassroots level for twenty years, distributing essential medications in local villages funded by USAID.

Mali made significant strides, with trachoma eradicated by 2023, and advances towards eliminating lymphatic filariasis. Nevertheless, recent funding cuts have placed these achievements in jeopardy. The decision by the Trump administration to halt USAID's program support was unexpected, leaving many, including Tounkara, without work.

Mamadou Coulibaly from Mali's Health Ministry echoed this sentiment, noting that the funding freeze has obstructed ongoing initiatives and post-treatment evaluations, vital for confirming disease eradication.

Prior to the cuts, USAID supplied diagnostic kits and funded personnel required for their deployment. These resources now languish unused in storage, nearing their expiration date.

Coulibaly and his team face a grim reality, actively searching for alternative financial backing without stable results. The absence of USAID's consistent support could undo years of progress, as diseases like trachoma risk resurging in already vulnerable regions.

The Broader Impact of NTDs

Neglected tropical diseases affect over a billion individuals globally, causing debilitating impairments. Despite their prevalence, these diseases often receive inadequate attention compared to headline-grabbing counterparts like HIV.

Historical records, including ancient hieroglyphics, document NTDs long before they were officially categorized.

USAID's NTD program emerged from a grassroots scientific effort in the early 2000s. Researchers argued for a planned approach involving annual treatments, aiming for long-term elimination.

Commencing in 2006, the program initially operated with a minimal budget, leveraging partnerships with pharmaceutical companies for drug donations. The idea was to facilitate mass drug distribution through donated resources.

The public-private partnership meant that while the U.S. provided oversight and support, local workers carried out the distribution, often involving door-to-door campaigns that were welcomed by communities.

Since its inception, the initiative treated over 1.7 billion individuals and achieved the elimination of one or more NTDs in fourteen countries, marking it as one of USAID's efficacious ventures.

Confronting Future Uncertainties

With a once stable annual budget of $114 million in 2021, the potential dissolution of these programs is a significant loss. Continuation efforts are hindered as countries struggle to replace nearly 90% of prior funding.

Helen Keller and similar organizations strive to garner alternative support but face limitations without federal backing, emphasizing the need for sustained U.S. investment.

Despite previous bipartisan support, future funding under the current administration appears unlikely, with new strategies omitting NTDs entirely. This leaves stakeholders scrambling to fill a substantial gap in global health aid.